Other systemic corticosteroids

In healthy adults given single oral doses of prednisone, investigators characterized conversion to prednisolone, systemic exposure, and cortisol suppression, showing rapid absorption, predictable conversion, and a clear dose‑dependent reduction in endogenous cortisol.

This systematic review analyzed 12 studies of systemic glucocorticoids, including work in healthy volunteers, and found substantial interindividual variability in pharmacokinetics for prednisone, prednisolone, methylprednisolone, and budesonide, with limited but suggestive evidence that higher prednisolone exposure is associated with more pronounced Cushingoid features.

Healthy volunteers receiving short courses of high-dose systemic glucocorticoids experienced transient increases in blood pressure, mood changes, sleep disturbance, and impaired glucose tolerance, underscoring that even brief exposure can alter metabolic and cardiovascular parameters.

In healthy adults receiving short courses of systemic prednisone, investigators observed increases in mood lability, anxiety, and insomnia compared with placebo, indicating that even brief systemic glucocorticoid use can affect mental well‑being and sleep quality.

This meta-analysis of randomized clinical trials involving systemic corticosteroids reported increased rates of new‑onset diabetes, hyperglycemia, and elevated blood pressure, along with other adverse events such as weight gain, dyslipidemia, insomnia, infections, osteoporosis, and fractures.

This trial found that short-term systemic glucocorticoid administration increased blood pressure and vascular responsiveness in both normotensive and hypertensive adults, suggesting that even brief exposure can adversely affect cardiovascular regulation.

Healthy volunteers receiving short courses of high-dose systemic glucocorticoids experienced transient increases in blood pressure, mood changes, sleep disturbance, and impaired glucose tolerance, underscoring that even brief exposure can alter metabolic and cardiovascular parameters.

This meta-analysis of randomized clinical trials involving systemic corticosteroids reported increased rates of new‑onset diabetes, hyperglycemia, and elevated blood pressure, along with other adverse events such as weight gain, dyslipidemia, insomnia, infections, osteoporosis, and fractures.

Healthy volunteers receiving short courses of high-dose systemic glucocorticoids experienced transient increases in blood pressure, mood changes, sleep disturbance, and impaired glucose tolerance, underscoring that even brief exposure can alter metabolic and cardiovascular parameters.

This meta-analysis of randomized clinical trials involving systemic corticosteroids reported increased rates of new‑onset diabetes, hyperglycemia, and elevated blood pressure, along with other adverse events such as weight gain, dyslipidemia, insomnia, infections, osteoporosis, and fractures.

This meta-analysis of randomized clinical trials involving systemic corticosteroids reported increased rates of new‑onset diabetes, hyperglycemia, and elevated blood pressure, along with other adverse events such as weight gain, dyslipidemia, insomnia, infections, osteoporosis, and fractures.

In a large cohort, systemic corticosteroid use was associated with dose‑dependent increases in fracture risk, with even relatively low daily doses linked to higher rates of vertebral and nonvertebral fractures compared with nonusers.

Healthy volunteers receiving short courses of high-dose systemic glucocorticoids experienced transient increases in blood pressure, mood changes, sleep disturbance, and impaired glucose tolerance, underscoring that even brief exposure can alter metabolic and cardiovascular parameters.

In healthy adults receiving short courses of systemic prednisone, investigators observed increases in mood lability, anxiety, and insomnia compared with placebo, indicating that even brief systemic glucocorticoid use can affect mental well‑being and sleep quality.

In a large cohort, systemic corticosteroid use was associated with dose‑dependent increases in fracture risk, with even relatively low daily doses linked to higher rates of vertebral and nonvertebral fractures compared with nonusers.

This meta-analysis of randomized clinical trials involving systemic corticosteroids reported increased rates of new‑onset diabetes, hyperglycemia, and elevated blood pressure, along with other adverse events such as weight gain, dyslipidemia, insomnia, infections, osteoporosis, and fractures.

In a large cohort, systemic corticosteroid use was associated with dose‑dependent increases in fracture risk, with even relatively low daily doses linked to higher rates of vertebral and nonvertebral fractures compared with nonusers.